Table 3.
HRs of bleeding for HD versus PD stratified for antithrombotic drug use, cardiovascular disease and prior bleeding
| Dialysis modality | Stratification level | n | Incidence rate/ 1000 person-years | NNT | Crude HR (95% CI) | Adjusted HR (95% CI) | Time-dependent adjusted HR (95% CI) |
|---|---|---|---|---|---|---|---|
| Antithrombotic drug use | |||||||
| PD | No | 430 | 30.0 | Reference | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| HD | No | 712 | 56.6 | 38 | 1.9 (1.2–2.9) | 1.6a (1.0–2.6) | 1.7a (1.1–2.7) |
| PD | Yes | 104 | 56.4 | 38 | 1.8 (0.9–3.7) | 1.7a (0.8–3.5) | 1.7a (0.8–3.4) |
| HD | Yes | 499 | 67.3 | 27 | 2.2 (1.4–3.4) | 1.8a (1.1–3.0) | 1.9a (1.1–3.1) |
| Cardiovascular disease | |||||||
| PD | No | 400 | 30.9 | Reference | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| HD | No | 721 | 58.2 | 37 | 1.9 (1.2–2.9) | 1.6b (1.0–2.6) | 1.8b (1.1–2.9) |
| PD | Yes | 134 | 47.4 | 61 | 1.5 (0.8–3.0) | 1.3b (0.6–2.6) | 1.5b (0.8–2.9) |
| HD | Yes | 490 | 65.0 | 29 | 2.1 (1.3–3.2) | 1.4b (0.8–2.3) | 1.4b (0.8–2.5) |
| Prior bleeding | |||||||
| PD | No | 511 | 34.4 | Reference | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| HD | No | 1116 | 56.5 | 45 | 1.6 (1.1–2.4) | 1.4c (0.9–2.1) | 1.4c (1.0–2.1) |
| PD | Yes | 19 | 50.0 | 64 | 1.4 (0.3–6.0) | 1.3c (0.3–5.5) | 0.7c (0.1–5.3) |
| HD | Yes | 83 | 133.1 | 10 | 3.8 (2.2–6.6) | 2.8c (1.6–5.1) | 3.0c (1.7–5.3) |
a
Adjusted for age, sex, primary kidney disease, prior bleeding, cardiovascular disease, erythropoietin use, arterial hypertension, residual GFR, haemoglobin and albumin.
b
Adjusted for age, sex, primary kidney disease, prior bleeding, antiplatelet drug use, vitamin K antagonist use, erythropoietin use, arterial hypertension, residual GFR, haemoglobin and albumin.
c
Adjusted for age, sex, primary kidney disease, cardiovascular disease, antiplatelet drug use, vitamin K antagonist use, erythropoietin use, arterial hypertension, residual GFR, haemoglobin and albumin.